CN110831974B - 针对血液恶性肿瘤的cd47靶向疗法的给药参数 - Google Patents

针对血液恶性肿瘤的cd47靶向疗法的给药参数 Download PDF

Info

Publication number
CN110831974B
CN110831974B CN201880040266.5A CN201880040266A CN110831974B CN 110831974 B CN110831974 B CN 110831974B CN 201880040266 A CN201880040266 A CN 201880040266A CN 110831974 B CN110831974 B CN 110831974B
Authority
CN
China
Prior art keywords
cells
dose
hu5f9
cell
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880040266.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN110831974A (zh
Inventor
拉温德拉·玛吉特
马克·P·超
刘劼
延斯-皮特·福尔克默
欧文·L·唔斯曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
47 LLC
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Forty Seven LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University, Forty Seven LLC filed Critical Leland Stanford Junior University
Priority to CN202310844109.2A priority Critical patent/CN117065013A/zh
Publication of CN110831974A publication Critical patent/CN110831974A/zh
Application granted granted Critical
Publication of CN110831974B publication Critical patent/CN110831974B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201880040266.5A 2017-06-21 2018-06-21 针对血液恶性肿瘤的cd47靶向疗法的给药参数 Active CN110831974B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310844109.2A CN117065013A (zh) 2017-06-21 2018-06-21 针对血液恶性肿瘤的cd47靶向疗法的给药参数

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762523182P 2017-06-21 2017-06-21
US62/523,182 2017-06-21
PCT/US2018/038798 WO2018237168A1 (en) 2017-06-21 2018-06-21 Dosing parameters for cd47 targeting therapies to hematologic malignancies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310844109.2A Division CN117065013A (zh) 2017-06-21 2018-06-21 针对血液恶性肿瘤的cd47靶向疗法的给药参数

Publications (2)

Publication Number Publication Date
CN110831974A CN110831974A (zh) 2020-02-21
CN110831974B true CN110831974B (zh) 2024-05-14

Family

ID=64735831

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880040266.5A Active CN110831974B (zh) 2017-06-21 2018-06-21 针对血液恶性肿瘤的cd47靶向疗法的给药参数
CN202310844109.2A Pending CN117065013A (zh) 2017-06-21 2018-06-21 针对血液恶性肿瘤的cd47靶向疗法的给药参数

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310844109.2A Pending CN117065013A (zh) 2017-06-21 2018-06-21 针对血液恶性肿瘤的cd47靶向疗法的给药参数

Country Status (12)

Country Link
US (3) US11141480B2 (https=)
EP (2) EP3642242B1 (https=)
JP (2) JP7312706B2 (https=)
KR (1) KR102757177B1 (https=)
CN (2) CN110831974B (https=)
AU (2) AU2018290248B2 (https=)
CA (1) CA3063099A1 (https=)
ES (1) ES2976558T3 (https=)
PL (1) PL3642242T3 (https=)
PT (1) PT3642242T (https=)
SI (1) SI3642242T1 (https=)
WO (1) WO2018237168A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3043181B1 (en) 2008-01-15 2020-04-08 The Board of Trustees of the Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
ES2582340T3 (es) 2008-01-15 2016-09-12 The Board Of Trustees Of The Leland Stanford Junior University Métodos para manipular fagocitosis mediada por CD47
US11072655B2 (en) * 2008-01-15 2021-07-27 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
WO2018237168A1 (en) * 2017-06-21 2018-12-27 The Board Of Trustees Of The Leland Stanford Junior University Dosing parameters for cd47 targeting therapies to hematologic malignancies
EA202190986A1 (ru) 2018-11-26 2021-12-14 Фоти Севен, Инк. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К c-Kit
US20200400662A1 (en) 2019-06-07 2020-12-24 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
ES2973832T3 (es) * 2019-10-18 2024-06-24 Forty Seven Inc Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda
CN121243368A (zh) * 2019-11-27 2026-01-02 Alx肿瘤生物技术公司 用于治疗癌症的组合疗法
CN111905101B (zh) * 2020-07-03 2022-09-23 中山大学 一种cd47抗体联合il-6细胞因子药在肿瘤治疗中的应用及验证其治疗肿瘤的方法
WO2022007947A1 (zh) * 2020-07-10 2022-01-13 信达生物制药(苏州)有限公司 抗cd47抗体或其抗原结合片段和dna甲基化转移酶抑制剂的组合及其用途
US20220196651A1 (en) 2020-12-06 2022-06-23 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
EP4291216A1 (en) * 2021-02-09 2023-12-20 University of Houston System Oncolytic virus for systemic delivery and enhanced anti-tumor activities
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
AU2024225341A1 (en) 2023-02-21 2025-09-04 Osteal Therapeutics, Inc. Methods of treating a localized infection with locally administered antibiotics

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102639565A (zh) * 2009-08-21 2012-08-15 坎塔吉亚有限责任公司 Il1rap在急性和慢性髓细胞样白血病细胞上的表达

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2543819T3 (es) 1998-11-09 2015-08-24 Biogen Inc. Tratamiento de neoplasias hematológicas asociadas con células tumorales circulantes utilizando anticuerpo quimérico dirigido contra CD20
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
EP3043181B1 (en) 2008-01-15 2020-04-08 The Board of Trustees of the Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
ES2582340T3 (es) * 2008-01-15 2016-09-12 The Board Of Trustees Of The Leland Stanford Junior University Métodos para manipular fagocitosis mediada por CD47
CA2771336C (en) * 2009-09-15 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
PT2569013T (pt) 2010-05-14 2017-02-08 Univ Leland Stanford Junior Anticorpos monoclonais humanizados e quiméricos para cd47
ES2816647T3 (es) 2012-01-17 2021-04-05 Univ Leland Stanford Junior Reactivos SIRP-alfa de alta afinidad
NZ710695A (en) * 2013-02-06 2020-05-29 Inhibrx Inc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
CN112245586A (zh) 2013-03-15 2021-01-22 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法
EP3046627B1 (en) 2013-09-18 2019-10-23 The Board of Trustees of the Leland Stanford Junior University Modulation of efferocytosis pathways for treatment of atherosclerotic disease
CN103943054B (zh) 2014-01-27 2016-07-13 上海中航光电子有限公司 栅极驱动电路、tft阵列基板、显示面板及显示装置
KR102271434B1 (ko) 2014-09-26 2021-07-01 엘지전자 주식회사 이동단말기 및 그 제어방법
CN113528663A (zh) 2014-12-10 2021-10-22 得克萨斯州大学系统董事会 使用基因组特异性探针的循环肿瘤和肿瘤干细胞检测
WO2017053423A1 (en) * 2015-09-21 2017-03-30 Erasmus University Medical Center Anti-cd47 antibodies and methods of use
WO2018237168A1 (en) 2017-06-21 2018-12-27 The Board Of Trustees Of The Leland Stanford Junior University Dosing parameters for cd47 targeting therapies to hematologic malignancies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102639565A (zh) * 2009-08-21 2012-08-15 坎塔吉亚有限责任公司 Il1rap在急性和慢性髓细胞样白血病细胞上的表达

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia;Patricia Font;《Adv Ther》;第28卷;摘要 *
Patricia Font.Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia.《Adv Ther》.2011,第28卷摘要. *
Targeting the leukemic stem cell:the holy grail of leukemia therapy;N Misaghian et al.;《Leukemia》;第25-42页 *
阿糖胞苷联合干扰素治疗白血病的研究进展;李斌;《广东化工》;第42卷(第42期);第109、131页 *

Also Published As

Publication number Publication date
US20200147212A1 (en) 2020-05-14
PL3642242T3 (pl) 2024-05-27
CN110831974A (zh) 2020-02-21
EP3642242B1 (en) 2024-02-07
JP2023083424A (ja) 2023-06-15
AU2024227248A1 (en) 2024-10-31
US12194093B2 (en) 2025-01-14
EP4368206A2 (en) 2024-05-15
JP2020525435A (ja) 2020-08-27
US12274746B2 (en) 2025-04-15
ES2976558T3 (es) 2024-08-05
CA3063099A1 (en) 2018-12-27
US20210401979A1 (en) 2021-12-30
EP4368206A3 (en) 2024-08-14
AU2018290248A1 (en) 2019-11-28
PT3642242T (pt) 2024-04-16
WO2018237168A1 (en) 2018-12-27
US20230270852A1 (en) 2023-08-31
US11141480B2 (en) 2021-10-12
EP3642242A1 (en) 2020-04-29
SI3642242T1 (sl) 2024-05-31
JP7312706B2 (ja) 2023-07-21
AU2018290248B2 (en) 2024-08-01
KR102757177B1 (ko) 2025-01-21
EP3642242A4 (en) 2021-06-23
KR20200019619A (ko) 2020-02-24
CN117065013A (zh) 2023-11-17

Similar Documents

Publication Publication Date Title
CN110831974B (zh) 针对血液恶性肿瘤的cd47靶向疗法的给药参数
Marin-Acevedo et al. Next generation of immune checkpoint therapy in cancer: new developments and challenges
AU2020202712B2 (en) Treatment of cancer with dual targeting of CD47 and EGFR
KR20200119834A (ko) 항-cd47 및 항-cd20 항체를 이용한 항암 섭생
KR102195055B1 (ko) 체크포인트 저해제와 조합된 종양용해 바이러스에 의한 암 요법
EP2271673A2 (en) Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof
KR102416144B1 (ko) 환자에서 항-cd19 치료법의 치료 이익의 예측 방법
JP2020517629A5 (https=)
HK40114200A (en) Dosing parameters for cd47 targeting therapies to hematologic malignancies
US20220119523A1 (en) Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway
HK40023801A (en) Dosing parameters for cd47 targeting therapies to hematologic malignancies
HK40103499A (zh) 针对血液恶性肿瘤的cd47靶向疗法的给药参数
HK40025478B (en) Dosing parameters for cd47 targeting therapies to hematologic malignancies
HK40025478A (en) Dosing parameters for cd47 targeting therapies to hematologic malignancies
HK40023801B (zh) 针对血液恶性肿瘤的cd47靶向疗法的给药参数
Navarrete-Sirvent Nk cells as biomarkers of response to antiegfr therapy in metastatic colorectal cancer: clinical implications and therapeutic opportunities
JP2025530188A (ja) 膀胱がんの治療において使用するための改変ｔ細胞

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40023801

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: California, USA

Patentee after: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR University

Country or region after: U.S.A.

Patentee after: 47 LLC

Address before: California, USA

Patentee before: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR University

Country or region before: U.S.A.

Patentee before: Forty-seven companies

CP03 Change of name, title or address